Diagnostic potential value of circulating PCA3 mRNA in plasma and urine of prostate cancer patients
Current reports show that most of the routinely available prostate specific antigen (PSA) derived biomarkers of prostate cancer (PCa) have failed to demonstrate sufficient sensitivity and specificity in clinical use for diagnosis and prognosis of PCa. Consequently, a number of molecular markers incl...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-09-01
|
| Series: | Scientific African |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468227622002502 |
| _version_ | 1797990925077577728 |
|---|---|
| author | Oluyemi Akinloye Olatunji I. Kareem Olayiwola A. Popoola Titilola A. Samuel Oluwatosin Adaramoye |
| author_facet | Oluyemi Akinloye Olatunji I. Kareem Olayiwola A. Popoola Titilola A. Samuel Oluwatosin Adaramoye |
| author_sort | Oluyemi Akinloye |
| collection | DOAJ |
| description | Current reports show that most of the routinely available prostate specific antigen (PSA) derived biomarkers of prostate cancer (PCa) have failed to demonstrate sufficient sensitivity and specificity in clinical use for diagnosis and prognosis of PCa. Consequently, a number of molecular markers including the prostate cancer gene 3 (PCA3) are being considered for clinical use. This study was therefore designed to determine the levels of PCA3 mRNA expression in urine and plasma of prostate cancer patients and to assess its diagnostic characteristics in Nigerian population with prostate cancer. A total of 90 participants comprising 30 participants each with PCa, BPH and 30 apparently healthy adults as controls were enrolled into this case-control study. Blood and urine samples were collected from study participants and dispensed into PaxGene RNA protecting fluid, lithium heparin bottles and nuclease free bottle as appropriate. Anthropometric indices were obtained using standard methods, while the plasma levels of PSA, testosterone and estrogen were determined using enzyme linked immunosorbent assay (ELISA). The PCA3 mRNA expression in urine and plasma was determined using Quantitative Polymerase Chain Reaction. Comparison of groups was done using analysis of variance (ANOVA) followed by Tukey Post-Hoc test. The sensitivity and specificity of PCA3 mRNA in the diagnosis of PCa was evaluated through estimation of the area under the receiver operating characteristic (ROC) curve. 'The mean waist circumference (WC) and (HC) was significantly higher in the BPH group (43.94 ± 2.32) compared to both the control (36.04 ± 0.80) and the PCa group (38.50 ± 0.94) (p < 0.05). The prostate cancer group had a significantly higher levels (p < 0.05) of tPSA (47.58 ± 12.23) and an increased expression of PCA3 mRNA in urine (10.46 ± 1.68) and plasma (14.89 ± 1.37) when compared with control values [tPSA (0.67 ± 0.27), urine (2.22 ± 0.22) and plasma (1.45 ± 0.13) expression of PCA3 mRNA]. A negative correlation was found to exist between Plasma PCa3 mRNA and plasma levels of estradiol (r=-0.425, p = 0.024) and testosterone (r=-0.423, p = 0.025) in PCa group. A similar trend was observed between urine PCA3 mRNA, estrogen (r=-0.459, p = 0.014) and testosterone (r=-0.407, p = 0.031). The ROC curve shows the tPSA (p = 0.03) is the most sensitive marker of detection followed by plasma PCA3 mRNA and subsequently the urine PCA3 mRNA. The curve further shows the urine PCA3 mRNA (p = 0.006) is the most specific for detection of prostate cancer and the less and least sensitive are the plasma PCA3 mRNA and tPSA. It could be concluded from this study that there is reduced levels of estradiol and testosterone and elevated levels of tPSA and PCA3 mRNA expression in urine and blood in patients with benign prostatic hyperplasia and prostate cancer. Hence, determination of plasma or urine expression of PCA3 mRNA is valueable in the diagnosis and treatment monitoring of prostate cancer. |
| first_indexed | 2024-04-11T08:43:51Z |
| format | Article |
| id | doaj.art-10ba5b99243341588804de0ce5fc6b88 |
| institution | Directory Open Access Journal |
| issn | 2468-2276 |
| language | English |
| last_indexed | 2024-04-11T08:43:51Z |
| publishDate | 2022-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Scientific African |
| spelling | doaj.art-10ba5b99243341588804de0ce5fc6b882022-12-22T04:34:02ZengElsevierScientific African2468-22762022-09-0117e01343Diagnostic potential value of circulating PCA3 mRNA in plasma and urine of prostate cancer patientsOluyemi Akinloye0Olatunji I. Kareem1Olayiwola A. Popoola2Titilola A. Samuel3Oluwatosin Adaramoye4Centre for Genomics of Non-Communicable Diseases and Personalized Healthcare, University of Lagos, Lagos, Nigeria; Department of Medical Laboratory Sciences, Faculty of Basic Medical Sciences, College of Medicine of the University of Lagos, PMB 12003, Idi-Araba, Lagos, Nigeria; Corresponding author at: Department of Medical Laboratory Sciences, Faculty of Basic Medical Sciences, College of Medicine of the University of Lagos, PMB 12003, Idi-Araba, Lagos, Nigeria.Centre for Genomics of Non-Communicable Diseases and Personalized Healthcare, University of Lagos, Lagos, Nigeria; Department of Medical Laboratory Sciences, Faculty of Basic Medical Sciences, College of Medicine of the University of Lagos, PMB 12003, Idi-Araba, Lagos, NigeriaCentre for Genomics of Non-Communicable Diseases and Personalized Healthcare, University of Lagos, Lagos, Nigeria; Department of Medical Laboratory Sciences, Faculty of Basic Medical Sciences, College of Medicine of the University of Lagos, PMB 12003, Idi-Araba, Lagos, NigeriaCentre for Genomics of Non-Communicable Diseases and Personalized Healthcare, University of Lagos, Lagos, Nigeria; Department of Biochemistry, Faculty of Basic Medical Sciences, College of Medicine of the University of Lagos, Lagos, NigeriaDepartment of Biochemistry, Faculty of Basic Medical Sciences, College of Medicine of the University of Ibadan, Oyo State, NigeriaCurrent reports show that most of the routinely available prostate specific antigen (PSA) derived biomarkers of prostate cancer (PCa) have failed to demonstrate sufficient sensitivity and specificity in clinical use for diagnosis and prognosis of PCa. Consequently, a number of molecular markers including the prostate cancer gene 3 (PCA3) are being considered for clinical use. This study was therefore designed to determine the levels of PCA3 mRNA expression in urine and plasma of prostate cancer patients and to assess its diagnostic characteristics in Nigerian population with prostate cancer. A total of 90 participants comprising 30 participants each with PCa, BPH and 30 apparently healthy adults as controls were enrolled into this case-control study. Blood and urine samples were collected from study participants and dispensed into PaxGene RNA protecting fluid, lithium heparin bottles and nuclease free bottle as appropriate. Anthropometric indices were obtained using standard methods, while the plasma levels of PSA, testosterone and estrogen were determined using enzyme linked immunosorbent assay (ELISA). The PCA3 mRNA expression in urine and plasma was determined using Quantitative Polymerase Chain Reaction. Comparison of groups was done using analysis of variance (ANOVA) followed by Tukey Post-Hoc test. The sensitivity and specificity of PCA3 mRNA in the diagnosis of PCa was evaluated through estimation of the area under the receiver operating characteristic (ROC) curve. 'The mean waist circumference (WC) and (HC) was significantly higher in the BPH group (43.94 ± 2.32) compared to both the control (36.04 ± 0.80) and the PCa group (38.50 ± 0.94) (p < 0.05). The prostate cancer group had a significantly higher levels (p < 0.05) of tPSA (47.58 ± 12.23) and an increased expression of PCA3 mRNA in urine (10.46 ± 1.68) and plasma (14.89 ± 1.37) when compared with control values [tPSA (0.67 ± 0.27), urine (2.22 ± 0.22) and plasma (1.45 ± 0.13) expression of PCA3 mRNA]. A negative correlation was found to exist between Plasma PCa3 mRNA and plasma levels of estradiol (r=-0.425, p = 0.024) and testosterone (r=-0.423, p = 0.025) in PCa group. A similar trend was observed between urine PCA3 mRNA, estrogen (r=-0.459, p = 0.014) and testosterone (r=-0.407, p = 0.031). The ROC curve shows the tPSA (p = 0.03) is the most sensitive marker of detection followed by plasma PCA3 mRNA and subsequently the urine PCA3 mRNA. The curve further shows the urine PCA3 mRNA (p = 0.006) is the most specific for detection of prostate cancer and the less and least sensitive are the plasma PCA3 mRNA and tPSA. It could be concluded from this study that there is reduced levels of estradiol and testosterone and elevated levels of tPSA and PCA3 mRNA expression in urine and blood in patients with benign prostatic hyperplasia and prostate cancer. Hence, determination of plasma or urine expression of PCA3 mRNA is valueable in the diagnosis and treatment monitoring of prostate cancer.http://www.sciencedirect.com/science/article/pii/S2468227622002502PCA3mRNAProstate cancerBenign prostatic hyperplasiaBloodUrine |
| spellingShingle | Oluyemi Akinloye Olatunji I. Kareem Olayiwola A. Popoola Titilola A. Samuel Oluwatosin Adaramoye Diagnostic potential value of circulating PCA3 mRNA in plasma and urine of prostate cancer patients Scientific African PCA3 mRNA Prostate cancer Benign prostatic hyperplasia Blood Urine |
| title | Diagnostic potential value of circulating PCA3 mRNA in plasma and urine of prostate cancer patients |
| title_full | Diagnostic potential value of circulating PCA3 mRNA in plasma and urine of prostate cancer patients |
| title_fullStr | Diagnostic potential value of circulating PCA3 mRNA in plasma and urine of prostate cancer patients |
| title_full_unstemmed | Diagnostic potential value of circulating PCA3 mRNA in plasma and urine of prostate cancer patients |
| title_short | Diagnostic potential value of circulating PCA3 mRNA in plasma and urine of prostate cancer patients |
| title_sort | diagnostic potential value of circulating pca3 mrna in plasma and urine of prostate cancer patients |
| topic | PCA3 mRNA Prostate cancer Benign prostatic hyperplasia Blood Urine |
| url | http://www.sciencedirect.com/science/article/pii/S2468227622002502 |
| work_keys_str_mv | AT oluyemiakinloye diagnosticpotentialvalueofcirculatingpca3mrnainplasmaandurineofprostatecancerpatients AT olatunjiikareem diagnosticpotentialvalueofcirculatingpca3mrnainplasmaandurineofprostatecancerpatients AT olayiwolaapopoola diagnosticpotentialvalueofcirculatingpca3mrnainplasmaandurineofprostatecancerpatients AT titilolaasamuel diagnosticpotentialvalueofcirculatingpca3mrnainplasmaandurineofprostatecancerpatients AT oluwatosinadaramoye diagnosticpotentialvalueofcirculatingpca3mrnainplasmaandurineofprostatecancerpatients |